EORTC 22996-24002/TROG 01.01 - EPO Head & Neck

By w.paterson
14 August, 2021
0 Comments

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases